Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cardiac arrhythmias
3.2.1.2 Advancements in antiarrhythmic drug development
3.2.1.3 Rising awareness and improved diagnosis
3.2.2 Industry pitfalls & challenges
3.2.2.1 Potential for severe side effects
3.2.2.2 Growing preference for non-pharmacological treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Patent analysis
3.8 Pipeline analysis
3.9 Clinical trial landscape
3.10 Gap analysis
3.11 Porter’s analysis
3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Sodium channel blockers (Class I)
5.3 Beta blockers (Class II)
5.4 Potassium channel blockers (Class III)
5.5 Calcium channel blockers (Class IV)
5.6 Other drug types
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Ventricular arrhythmias
6.3 Supraventricular arrhythmias
6.4 Other disease types
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 E-commerce
8.5 Other distribution channels
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Astellas Pharma
10.3 AstraZeneca
10.4 Baxter International
10.5 Bayer AG
10.6 Bristol-Myers Squibb
10.7 GlaxoSmithKline
10.8 Johnson & Johnson
10.9 Milestone Pharmaceuticals
10.10 Novartis International
10.11 Pfizer
10.12 Sanofi
10.13 Teva Pharmaceutical Industries
10.14 Upsher-Smith Laboratories
10.15 Viatris
